Clinical Characteristics, Autoantibody Profiles, and Therapeutic Outcomes of Juvenile Systemic Sclerosis: An 11-Year Single-Center Experience from China - Takeaways - MDSpire

Clinical Characteristics, Autoantibody Profiles, and Therapeutic Outcomes of Juvenile Systemic Sclerosis: An 11-Year Single-Center Experience from China

  • By

  • Wang, Yating

  • Tang, Wenjing

  • Zhang, Yu

  • Zhang, Zhi-Yong

  • An, Yunfei

  • Tang, Xuemei

  • April 29, 2026

  • 0 min

Share

  • 1

    Juvenile systemic sclerosis (jSSc) is a rare but severe rheumatic condition affecting pediatric growth and development.

  • 2

    Skin sclerosis was the predominant symptom observed in all 21 pediatric jSSc patients studied.

  • 3

    Antinuclear antibody (ANA) was positive in 76.2% of patients, with anti-single-stranded DNA being the most common specific antibody.

  • 4

    Significant reductions in overall disease severity and skin involvement were noted after 24 months of treatment.

  • 5

    No fatalities or severe adverse events occurred during the follow-up period, highlighting the safety of the treatment approaches.

Original Source(s)

Clinical Characteristics, Autoantibody Profiles, and Therapeutic Outcomes of Juvenile Systemic Sclerosis: An 11-Year Single-Center Experience from China

  • by Wang, Yating , Tang, Wenjing , Zhang, Yu , Zhang, Zhi-Yong , An, Yunfei , Tang, Xuemei

  • April 29, 2026

Related Content

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

SSc May Be Linked to Subtle Cognitive Changes

Cross-sectional study finds domain-specific differences and higher anxiety without global impairment.

Multi-omics analyses reveal significant differences in the gut microbiota and metabolites in children with Kawasaki disease in Northwest China